Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioAffinity TechnologiesBIAF +5.07%44 3-Year EBITDA Growth Rate is 39.40% as of Jun. 2026, which is 32% above its 10-year median of 29.80. GuruFocus rates BIAF with a GF Scoreâ„¢ of 44/100 and a GF Valueâ„¢ of $1.90 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, bioAffinity Technologies ranks better than 78.18% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 39.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of bioAffinity Technologies was 39.40% per year. The lowest was 29.30% per year. And the median was 29.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
bioAffinity Technologies 3-Year EBITDA Growth Rate Related Terms
BIAF vs FUNI, ISPC, NDRA: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, bioAffinity Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 39.40% mean?
bioAffinity Technologies (BIAF) has a 3-Year EBITDA Growth Rate of 39.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for bioAffinity Technologies and its competitors. This is 32% above median its historical median of 29.80. Over the past decade, bioAffinity Technologies' 3-Year EBITDA Growth Rate has ranged from 29.30 to 39.40. According to the industry distribution chart, bioAffinity Technologies ranks #36 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 21.8%.
Is bioAffinity Technologies' 3-Year EBITDA Growth Rate too high?
bioAffinity Technologies' current 3-Year EBITDA Growth Rate of 39.40% is 32% above median its 10-year median of 29.80. Over the past 10 years, this metric has ranged from a low of 29.30 to a high of 39.40. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.50. bioAffinity Technologies' value of 39.40% is 242.6% above this industry median. Based on the distribution chart, bioAffinity Technologies ranks #36 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' 3-Year EBITDA Growth Rate compare to FUNI and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #36 out of 165 companies for 3-Year EBITDA Growth Rate. This places bioAffinity Technologies in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.50. bioAffinity Technologies' value of 39.40% is 242.6% above this benchmark. Historically, bioAffinity Technologies' own 3-Year EBITDA Growth Rate has ranged from 29.30 to 39.40 over the past decade. While the company's 10-year median is 29.80 vs. the industry median of 11.50, bioAffinity Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.50, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioAffinity Technologies's current 3-Year EBITDA Growth Rate of 39.40% is 242.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current 3-Year EBITDA Growth Rate is 39.40%, which is 32% above median its own 10-year median of 29.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.90, compared to a current price of $0.40 — trading 78.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 39.40%, which is 32% above median its 10-year median of 29.80 and 242.6% above the Medical Diagnostics & Research industry median of 11.50. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current 3-Year EBITDA Growth Rate is 39.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.40 is trading 78.8% below its estimated GF Value™ of $1.90.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
3-Year EBITDA Growth Rate: 39.40% (32% above median its 10-year median of 29.80)
GF Value™: $1.90 vs. price of $0.40 (78.8% below fair value)
Industry Position: 242.6% above the Medical Diagnostics & Research median (#36 of 165)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
